Back

Efficacy comparison of prostacyclin analogue and prostacyclin receptor agonist as third line treatment for pulmonary arterial hypertension

27 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Current treatment of pulmonary hypertension: it is all about vasodilators Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Giulia martini

University Hospital of Bologna S. Orsola-Malpighi Polyclinic, Bologna (Italy)

7 More presentations in this session

Presentation thumbnail
Effect of a short course of parenteral treprostinil therapy on right heart structure and function in pulmonary arterial hypertension
Doctor C. Vizza (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Triple therapy for incident pulmonary arterial hypertension in Finland between 2008 and 2020. A descriptive real-world FINPAH cohort study
Doctor M. Pentikainen (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
Macitentan tadalafil Fixed Dose Combination (FDC) in treatment-naive and prior monotherapy patients with Pulmonary Arterial Hypertension (PAH): insights from A DUE
Professor P. Jansa (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
The effect of sildenafil on maternal mortality in pulmonary arterial hypertension associated with congenital heart disease
Doctor N. Nahdi (Yogyakarta, ID)
Abstract Slides Video
Presentation thumbnail
Specific therapies of pulmonary hypertension and prognosis in COVID-19: 18-months analysis of BNP-PL national database.
Doctor A. Mamzer (Lodz, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Current treatment of pulmonary hypertension: it is all about vasodilators

The Event

Event poster

ESC Congress 2023

27 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Comparison of triple oral and triple parenteral combination therapy in pulmonary arterial hypertension
thumbnail
Congress Presentation
Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study
thumbnail
Congress Presentation
Evaluating the safety and long-term efficacy of triple vasodilator therapy for pulmonary arterial hypertension associated with congenital heart disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources